Epsilon Healthcare Limited
0.02
AUD
+0.00
(-13.04%)
ISIN
AU0000137598
Return %
Stock
S&P 500
1Y
-16.67
14.20
3Y
-25.93
81.12
5Y
-87.10
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Peter Giannopoulos
- Full Time Employees
- 14
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 5 Goodyear Street Southport QLD Australia 4215
- IPO Date
- May 3, 2017
- Website
- epsilonhealthcare.com.au
- Similar Companies
- Business
- Epsilon Healthcare Limited (ASX:EPN) is an Australia-based diversified global healthcare and pharmaceuticals company focused on medicinal cannabis, contract development and manufacturing, telehealth medical practices, and pharmacy services. The company offers GMP pharmaceutical manufacturing through its Southport Facility, the largest cannabis extraction and manufacturing site in the Southern Hemisphere with TGA and EU GMP certifications; cannabis medicine development via licensed bio-floral extraction; specialist healthcare clinics under Tetra Health with access to over 600 prescribing physicians; the Medimar Platform, an end-to-end ecommerce solution for nutraceuticals, wellness products, and medicinal cannabis access for prescribers, pharmacies, patients, and suppliers; and turnkey cannabis cultivation solutions including hydroponic equipment wholesale and retail from its Vancouver, Canada-based operations, complemented by licensed medicinal cannabis retailing and nursery services. Epsilon Healthcare operates primarily in Australia and Canada, targeting patients with chronic conditions, healthcare providers, pharmacies, and cultivators; it was incorporated in 2016, listed on the ASX in May 2017, and maintains headquarters in Sydney, New South Wales. Recent developments include execution of a Deed of Company Arrangement for subsidiary Epsilon Pharma Pty Ltd in April 2025 to extinguish creditor claims; securing $1 million in funding in May 2025 alongside cost-reduction initiatives in Q4 2024 and Q1 2025; an extraordinary general meeting in June 2025; a trading suspension in August 2025 for unpaid listing fees; director Alan Beasley acquiring 10 million unlisted shares; and completion of interdependent Deeds of Company Arrangement for pharma and clinics segments in mid-2024 following voluntary administration, alongside brand alignment for new pharmacy subsidiaries launched from late 2023.